Genetic Technologies Ltd
Company Profile
- Business description- Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate. 
- Contact- 60-66 Hanover Street 
 Fitzroy
 MelbourneVIC3065
 AUS- T: +61 384127000 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Diagnostics & Research - Fiscal Year End- 30 June 2026 - Employees- 60 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,121.07 | 79.81 | -0.97% | 
| DAX 40 | 23,958.30 | 160.59 | -0.67% | 
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% | 
| FTSE 100 | 9,717.25 | 42.81 | -0.44% | 
| HKSE | 25,906.65 | 376.04 | -1.43% | 
| NASDAQ | 23,724.96 | 143.81 | 0.61% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,840.20 | 17.86 | 0.26% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |